Vismed (sodium hyaluronate) / TRB Chemedica - LARVOL DELTA

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: Santen SAS | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Sep 2026 | Trial primary completion date: Dec 2024 ➔ Sep 2026

Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=83 | Completed | Sponsor: Santen SAS | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Apr 2025 | Trial primary completion date: Dec 2024 ➔ Apr 2025

Head-to-Head • Trial completion • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Vaccines Assessment: different approaches on serological assays (WVCE 2024) - "Sponsored by: Vismederi"

Overview of 37 Tear Substitutes in Europe Based on Various Physicochemical Parameters. (PubMed, Ophthalmol Ther) - "While the perfect eye drop does not exist, a multitude of options are available to choose from. This study improves our understanding of the major tear substitutes available on the European market based on several physicochemical properties. A better understanding and awareness of these parameters is crucial in order to offer the best treatment for patients with DED."

Journal • Dry Eye Disease • Ophthalmology

A randomised study comparing performance and safety of Eyestil Plus® vs Vismed Multi® in moderate-to-severe dry eye syndrome patients. (PubMed, Eur J Ophthalmol) - "This clinical investigation showed the non-inferiority of Eyestil Plus® compared to Vismed Multi® regarding performance and safety in a moderate-to-severe DED population."

Journal • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Sjogren's Syndrome

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome (clinicaltrials.gov) - P=N/A | N=226 | Recruiting | Sponsor: Laboratoires Thea | Not yet recruiting ➔ Recruiting

Enrollment open • Dry Eye Disease • Ophthalmology

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Oct 2023 ➔ Dec 2024 | Trial primary completion date: Oct 2023 ➔ Dec 2024

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome (clinicaltrials.gov) - P=N/A | N=226 | Not yet recruiting | Sponsor: Laboratoires Thea

New trial • Dry Eye Disease • Ophthalmology

Randomized Clinical Trial of Topical Insulin Versus Artificial Tears for Healing Rates of Iatrogenic Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. (PubMed, Cornea) - "Topical insulin (0.5 units, 4 times per day) is more effective compared with artificial tears (Vismed, sodium hyaluronate 0.18%, 4 times per day) for the healing of postoperative corneal epithelial defects induced during vitreoretinal surgery in diabetic patients, without any adverse events."

Clinical • Journal • Surgery • Diabetes • Metabolic Disorders

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Feb 2023 ➔ Oct 2023 | Trial primary completion date: Oct 2022 ➔ Oct 2023

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Jul 2023 ➔ Dec 2023 | Trial primary completion date: Apr 2023 ➔ Dec 2023

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

"@Microbiologics @newsfrom_MP @Merck @Microbiologics @naobios @OsivaxVaccines @PrecisionNano @sanofi @serimmune @SibrosTech @Studykik @TouchlightDNA @utmbhealth @Vaxart @Vaxess @VBIVaccines @vernalbio @VisMederi" (@vaccinenation)

Clinical

Idroflog® for Treatment of Dry Eye Disease (IDROFLOG) (clinicaltrials.gov) - P=N/A | N=130 | Not yet recruiting | Sponsor: Alfa Intes Industria Terapeutica Splendore s.r.l.

New trial • Dry Eye Disease • Ophthalmology

A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi® (clinicaltrials.gov) - P=N/A | N=96 | Completed | Sponsor: SIFI SpA | Active, not recruiting ➔ Completed

Head-to-Head • Trial completion • Dry Eye Disease • Ocular Inflammation • Ophthalmology

"@vismed3D @WomenInMedicine @womenandmed @ptkirchgraber @UChicago @UWMedicine @PennMedicine @UofIllinois @NorthShoreWeb @WeinbergCollege @NorthwesternU @RushMedical @avolgman @DoctorADDA @BrownMedAMWA @IUSMDeptMed @RFUniversity @SmartHealth_NUS @IUVentures @IUWellsCenter" (@dimaelissa)

Clinical

"@VaxtrialsO @VisMederi @UKHSA @Tofflon @SEPPIC @Roche @PallCorporation @novotechCRO @Microbiologics @MeridianClinRes @LeukocareAG @JuliusClinical @IVIHeadquarters @CleanCells @BIOASTER @Asphalion @Allucent_CRO @ACROBio @3PBio @Mabtech @CEVAXIN_PTY @provepharm" (@vaccinenation)

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2022 ➔ Feb 2023 | Trial primary completion date: Apr 2022 ➔ Oct 2022

Enrollment open • Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Jul 2022 ➔ Apr 2023

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance (clinicaltrials.gov) - P=N/A | N=21 | Terminated | Sponsor: SIFI SpA | SIFI has developed a new product with probably a better performance. SIFI changed its marketing strategy and decided that Eyestil® Protection will be not marketed anymore

Enrollment change • Head-to-Head • Trial termination • Dry Eye Disease • Ocular Inflammation • Ophthalmology

A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi® (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: SIFI SpA | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2021 ➔ Aug 2022 | Trial primary completion date: Dec 2021 ➔ May 2022

Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Dry Eye Disease • Ocular Inflammation • Ophthalmology

[VIRTUAL] Renal Transplant Recipient with Large Periorbital Basal Cell Carcinoma (BCC) Cured Nonsurgically with Vismodegib (KIDNEY WEEK 2021) - "We present a case of a RTR who developed invasive periorbital BCC; successfully treated with novel chemotherapeutic Vismodegib Case Description A 66-year-old man with history of kidney transplant had a stable graft function with Cr 1.6 on IS for 35 years, on Prednisone and Tacrolimus...Our case highlights that Vismedogib is efficacious in preserving essential visual structures and eyesight even in much larger tumor burden; 55mm. In conclusion, Vismodegib is now emerging in critical management of large and fast growing BCC affecting vital facial structures, especially in RTR on long term IS meds."

Clinical • Basal Cell Carcinoma • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Ophthalmology • Skin Cancer • Transplantation

RESTA: A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye (clinicaltrials.gov) - P=N/A; N=92; Completed; Sponsor: Laboratoire Chauvin; Active, not recruiting ➔ Completed; Trial completion date: Jul 2020 ➔ Mar 2021

Clinical • Trial completion • Trial completion date • Dry Eye Disease • Ocular Inflammation • Ophthalmology

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A; N=80; Not yet recruiting; Sponsor: Santen SAS; Initiation date: Jun 2021 ➔ Sep 2021

Clinical • Head-to-Head • Trial initiation date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Efficacy of T2259 in DED (clinicaltrials.gov) - P=N/A; N=90; Completed; Sponsor: Laboratoires Thea; Recruiting ➔ Completed

Clinical • Trial completion • Dry Eye Disease • Keratitis • Ocular Inflammation • Ophthalmology